Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies.

Cardiovasc Ther · 2022 · PMC9203223 · PMID 35801133

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

A random-effects meta-analysis of all studies showed a strong trend towards reduced risk of recurrent PE in the RIV group, although the result was imprecise due to a high level of heterogeneity ( I 2 = 70%).

also in 5,725 other papers

a nonsignificant trendno p-value reported

The AMPLIFY trial reported an HR of 0.84 for the risk of recurrent VTE, indicating a nonsignificant trend towards lower event risk in the API group, which was confirmed in this meta-analysis, which pooled data from 74,345 patients (HR = 0.83 (0.73, 0.93)).

also in 5,406 other papers

showed a trendno p-value reported

The analysis of predefined secondary outcomes of the EINSTEIN DVT trial demonstrated the superiority of RIV over SoC regarding the net clinical benefit, defined as the composite of recurrent VTE and major bleeding events (HR = 0.67 (0.47, 0.95)), and showed a trend towards a lower risk of death (HR = 0.67 (0.44, 1.02)).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.